Patents by Inventor Eliud Oloo

Eliud Oloo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242918
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: April 11, 2022
    Publication date: August 4, 2022
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN
  • Patent number: 11325947
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 10, 2022
    Assignee: SANOFI PASTEUR INC.
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Publication number: 20220054623
    Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 24, 2022
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Patent number: 11116832
    Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 14, 2021
    Assignee: SANOFI PASTEUR INC.
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Publication number: 20210147488
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: October 21, 2020
    Publication date: May 20, 2021
    Inventors: Tod Strugnell, Eliud Oloo
  • Publication number: 20210128715
    Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 6, 2021
    Applicant: Sanofi Pasteur Inc.
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN, Thorsten VOGEL, Harold KLEANTHOUS
  • Publication number: 20210046176
    Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant neuraminidase (NA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant NA polypeptides.
    Type: Application
    Filed: March 27, 2019
    Publication date: February 18, 2021
    Applicants: SANOFI PASTEUR INC., VIB VZW, UNIVERSITEIT GENT
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen, Thorsten Vogel, Xavier Saelens, Emma Job
  • Patent number: 10844097
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 24, 2020
    Assignee: Sanofi Pasteur Inc.
    Inventors: Tod Strugnell, Eliud Oloo
  • Publication number: 20200223892
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 16, 2020
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Publication number: 20200215182
    Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 9, 2020
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Patent number: 10584148
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: March 10, 2020
    Assignee: SANOFI PASTEUR INC.
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Publication number: 20190161519
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 30, 2019
    Inventors: Tod Strugnell, Eliud Oloo
  • Publication number: 20180298063
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 18, 2018
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN
  • Patent number: 9546199
    Abstract: This disclosure relates to immunogenic compositions comprising mutant Streptococcus pneumonia pneumolysin (PLY) proteins. Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 17, 2017
    Assignee: The Kingdom of The Netherlands, Represented by The Minister of Health, Welfare and Sport, On Behalf of The Minister, The National Institute of Public Health and The Environment
    Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs-Onolemhemhen, Jeremy Yethon
  • Publication number: 20150376242
    Abstract: This disclosure relates to immunogenic compositions comprising mutant Streptococcus pneumonia pneumolysin (PLY) proteins. Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.
    Type: Application
    Filed: December 18, 2014
    Publication date: December 31, 2015
    Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs, Jeremy Yethon
  • Patent number: 8951531
    Abstract: This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by S. pneumonia The modified pneumolysm proteins comprise amino acid substitutions at threonine 65, glycine 293 and cysteine 428 Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: February 10, 2015
    Assignee: The Kingdom of the Netherlands, Represented by the Minister of Health, Welfare and Sport, on Behalf of the Minister, The National Institute of Public Health and the Environment
    Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs-Onolemhemhen, Jeremy Yethon
  • Publication number: 20140341942
    Abstract: This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by S.
    Type: Application
    Filed: May 5, 2014
    Publication date: November 20, 2014
    Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs, Jeremy Yethon
  • Patent number: 8758766
    Abstract: This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by S. pneumonia. The modified pneumolysm proteins comprise ammo acid substitutions at threonine 65, glycine 293 and cysteine 428 Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: June 24, 2014
    Assignee: The Kingdom of The Netherlands, Represented by The Mininster of Health, Welfare and Sport, on Behalf of The Minster The National Institute of Public Health and The Environment
    Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs, Jeremy Yethon
  • Publication number: 20110287046
    Abstract: This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by S. pneumonia.
    Type: Application
    Filed: December 22, 2009
    Publication date: November 24, 2011
    Inventors: Eliud Oloo, Raymond Oomen, Martina Ochs, Jeremy Yethon